Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Daiichi Sankyo
Deloitte
Queensland Health
Citi
Express Scripts
Boehringer Ingelheim
Teva

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205579

« Back to Dashboard

NDA 205579 describes RYANODEX, which is a drug marketed by Eagle Pharms and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the RYANODEX profile page.

The generic ingredient in RYANODEX is dantrolene sodium. There are five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.
Summary for 205579
Tradename:RYANODEX
Applicant:Eagle Pharms
Ingredient:dantrolene sodium
Patents:5
Therapeutic Class:Antispasticity Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 205579
Medical Subject Heading (MeSH) Categories for 205579
Suppliers and Packaging for NDA: 205579
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579 NDA Eagle Pharmaceuticals, Inc. 42367-540 N 42367-540-32

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;INTRAVENOUSStrength250MG/VIAL
Approval Date:Jul 22, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 22, 2021
Regulatory Exclusivity Use:TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
Patent:➤ Try a Free TrialPatent Expiration:Jul 1, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Dec 24, 2022Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Harvard Business School
Merck
Farmers Insurance
Fuji
Teva
UBS
Queensland Health
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.